AUA: Advanced Prostate Cancer (2023): Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 40: | Line 40: | ||
***#* '''<span style="color:#ff0000">High specificity and sensitivity</span>''' | ***#* '''<span style="color:#ff0000">High specificity and sensitivity</span>''' | ||
***#** '''<span style="color:#ff0000">Outperforms standard CT and MRI in detection of nodal and osseous metastases.</span>''' | ***#** '''<span style="color:#ff0000">Outperforms standard CT and MRI in detection of nodal and osseous metastases.</span>''' | ||
***#*** In a recent prospective study of men who had undergone prostatectomy and had a rising PSA still under 2.0ng/mL, PSMA-PET detected occult metastases 4.54x significantly more frequently than fluciclovine- | ***#*** In a recent prospective study of men who had undergone prostatectomy and had a rising PSA still under 2.0ng/mL, PSMA-PET detected occult metastases 4.54x significantly more frequently than fluciclovine-PET[https://pubmed.ncbi.nlm.nih.gov/31375469/ §] | ||
***#** At the time of guideline publication, had not received FDA approval in the U.S. '''Received FDA approval''' in December 2020.§ | ***#** At the time of guideline publication, had not received FDA approval in the U.S. '''Received FDA approval''' in December 2020.[https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer §] | ||
***# '''<span style="color:#ff0000">11C-choline</span>''' | ***# '''<span style="color:#ff0000">11C-choline</span>''' | ||
***#* '''Lower sensitivity and specificity for metastatic disease''' | ***#* '''Lower sensitivity and specificity for metastatic disease''' | ||